Core Cap Advisors, LLC C4 Therapeutics, Inc. Transaction History
Core Cap Advisors, LLC
- $2.12 Billion
- Q4 2024
A detailed history of Core Cap Advisors, LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 128 shares of CCCC stock, worth $407. This represents 0.0% of its overall portfolio holdings.
Number of Shares
128Holding current value
$407% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
124Shares Held
65.2MCall Options Held
544KPut Options Held
30.3K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$22.2 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$21.8 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$19.3 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$15.5 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$14.5 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $156M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...